Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Charles Gore

Charles Gore, The Hepatatis C Trust

My name is Charles Gore and I am the Chief Executive of the Hepatitis C Trust. 

It has been really nice to have been involved with STOP-HCV because they have really concentrated on trying to come up with answers that met the questions that patients have, not just the more theoretical research questions but really things that will benefit us.  It is about why do I not respond to treatment, because if the treatment doesn’t work, patients really want to know, is it something I have done or is it just that I have been unlucky because I have, for example, particular genetic markers in me that just makes treatment not work and maybe that means that I need different combinations of treatment?  But there may be examples in which the ways this project will come up with results that will really make a difference and make it better for us as patients.

In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.